Adventus Laboratories (India) Profile
Key Indicators
- Authorised Capital ₹ 6.60 Cr
- Paid Up Capital ₹ 3.38 Cr
- Company Age 16 Year, 28 Days
- Last Filing with ROC 31 Mar 2023
- Revenue Growth -47.19%
- Profit Growth -20.78%
- Ebitda -25.72%
- Net Worth 9.08%
- Total Assets -21.17%
About Adventus Laboratories (India)
Adventus Laboratories (India) Private Limited (ALIPL) is a leading Private Limited Indian Non-Government Company incorporated in India on 28 January 2009 and has a history of 16 years. Its registered office is in Vadodara, Gujarat, India.
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 6.60 Cr and a paid-up capital of Rs 3.38 Cr, as per Ministry of Corporate Affairs (MCA) records.
Vaibhav Valodkar and Neeta Valodkar serve as directors at the Company.
Company Details
- Location
Vadodara, Gujarat, India
- Telephone
+91-XXXXXXXXXX
- Email Address
- Website
- Social Media
Corporate Identity Details
- CIN/LLPIN
U24100GJ2009PTC055988
- Company No.
055988
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
28 Jan 2009
- Date of AGM
27 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Ahmedabad
Industry
Who are the key members and board of directors at Adventus Laboratories (India)?
Executive Team (1)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Vaibhav Valodkar  | Managing Director | 08-Jan-2015 | Current |
Board Members (1)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
| Neeta Valodkar | Director | 19-Feb-2020 | Current |
Financial Performance of Adventus Laboratories (India).
Adventus Laboratories (India) Private Limited, for the financial year ended 2023, experienced significant reduction in revenue, with a 47.19% decrease. The company also saw a substantial fall in profitability, with a 20.78% decrease in profit. The company's net worth moved up by a moderate rise of 9.08%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Adventus Laboratories (India)?
In 2023, Adventus Laboratories (India) had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Adventus Laboratories (India)?
Adventus Laboratories (India) has a workforce of 9 employees as of Apr 01, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Adventus Laboratories (India), offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Adventus Laboratories (India)'s trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
